A Plea for Freedom:

http://www.infowars.com/a-plea-for-freedom/

THIS IS A MUST READ!!!...IMO

It's one of the best articles I've read all year...

Today - Cyclacel Pharmaceuticals (CYCC) - Had it's Highest Volume Day, and Highest Close in a Month:

I haven't talked about my favorite microcap biotech company in a while, because there hasn't been a lot to talk about...There have been some interesting developments in the past month or so, that haven't increased the share price of the stock, even though I think one of them should have...

The first piece of interesting news has to do with a patent infringement case between Celgene (Nasdaq - CELG) and Cyclacel:

BERKELEY HEIGHTS, N.J., June 18, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC - News) (Nasdaq:CYCCP - News), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it filed its Answer and Counterclaims to the declaratory judgment complaint filed by Celgene Corporation. Cyclacel has filed counterclaims charging Celgene with infringement of each of four Cyclacel-owned patents and seeks damages for Celgene's infringement as well as injunctive relief. The four patents directly involve the use and administration of Celgene's ISTODAX(R) (romidepsin for injection) product.

The declaratory judgment complaint seeks to have the four Cyclacel patents, which claim the use of romidepsin for injection in T-cell lymphomas, declared invalid and not infringed by Celgene's products.

The four Cyclacel patents which are the subject of this action do not involve Cyclacel's clinical development candidates or its commercial products.

(The bottom line here is Celgene is infringing on Cyclacel's patents!...not the other way around...If CELG loses this patent infringement case, they will owe CYCC a nice chunk of change...IMO)

http://finance.yahoo.com/news/Cyclacel-Answers-Celgenes-pz-2925157020.html?x=0&.v=1

On June 28, 2010 it was PR'd that:

CYCC had been added to the Russell Microcap Index:

(This means that a lot of Hedge Funds must buy shares of CYCC if they don't already own them...)

http://finance.yahoo.com/news/Cyclacel-Pharmaceuticals-pz-3695109373.html?x=0&.v=1

The most interesting development was the announcement on July 1st that:

Cyclacel Pharmaceuticals Announces FDA Orphan Drug Designation for their lead drug Sapacitabine in Both AML and MDS:

"Orphan drug designation for both AML and MDS significantly strengthens the value proposition represented by sapacitabine and enhances our opportunity to advance this promising product candidate to late stage clinical development and commercialization," said Spiro Rombotis, President and Chief Executive Officer of Cyclacel.

Orphan drug designation entitles Cyclacel Pharmaceuticals to seven years of marketing exclusivity for sapacitabine upon regulatory approval, as well as the opportunity to apply for grant funding from the U.S. government to defray costs of clinical trial expenses, tax credits for clinical research expenses and a potential waiver of the FDA's application user fee. Orphan status is granted by the FDA to promote the development of new drug therapies for the treatment of diseases that affect fewer than 200,000 individuals in the United States.

(There was a huge Volume spike that day, but not much upward movement of the share price that day or in the days that followed...Personally, I think this is HUGE news and the share price should've move north because of it, but the overall market was in dump mode during this period and the biotech sector as a whole was pretty badly beaten up...)

http://finance.yahoo.com/news/Cyclacel-Pharmaceuticals-pz-2152455345.html?x=0&.v=1

Yesterday, the company announced the date they'll release Q2 Earnings and host a Conference Call:

Cyclacel Pharmaceuticals to Announce Release of Second Quarter 2010 Financial Results:

CYCC will announce second quarter 2010 financial results on Thursday, August 5, 2010. The Company will host a conference call and live webcast at 4:30 pm Eastern time on the same day.

Conference call information:

U.S./Canada call: (877) 493-9121/ international call: (973) 582-2750

U.S./Canada archive: (800) 642-1687 / international archive: (706) 645-9291

Code for live and archived conference call is 91437070

For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com The webcast will be archived for 90 days and the audio replay for 7 days.

(EarningsWhispers.com says their projected earnings for last quarter are ($0.17), which would beat the previous quarter's actual earnings of ($0.18) by a penny...Also notice in the Analysts Recommendation section CYCC is listed as a "Strong Buy":)

http://www.earningswhispers.com/stocks.asp?symbol=CYCC

And now for the charts:

As you can see, the candlestick hit the upper Bollinger Band (BB) on the daily chart for the first time in three months...Unfortunately, I never buy AT the upper BB even if the candlestick formed today is very tall, white, bullish, and closed only two cents below the high of the day...I'm not saying it can't go up any further, but this is where I usually take profits if I was actually trading in and out of this stock...Which I'm not...I own a nice block of shares bought at $1.45 on July 20th when the hourly (and daily) chart said it was time to get back IN:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=52462152

Now that I'm up nearly three grand, did I take profits today?....NO!...Why?...Because news about the SPA is nearly a month overdue from when the CEO said to expect it during last quarter's conference call...Why the delay?...Because SPA's are a back and forth dialog between the FDA and the company that creates a Phase III trial that uses the FDA's design protocols...While SPA's are not guarantees that the Phase III trial will be successful and lead up to FDA approval of the drug, it greatly increases the chances for success...I think the delay in announcing the SPA has been due to a continuing dialog between the FDA and the company that is in the process of altering and improving the Phase III trial design...So there has been another delay...So what?...If the trial is now on track to be safer and more effective, I don't mind another small delay...I truly believe that if the SPA had been denied, we would have heard about that by now...

The reason I won't sell my block of shares today is because news about the SPA could come anytime between now and the CC, and if you're not IN when this news is PR'd, you will miss out on a nice spike up, and you'll be chasing the price higher after the PR is released...Especially if the SPA is followed immediately by news of a partnership with a big pharma company to help fund and execute the Phase III trial...If that happens, I'm pretty sure we will see a very large spike up in a very short period of time...And when I see that spike, I'll probably lock in my profits as close to the top as I can, because there will be a long quiet period for news after these two things are announced...

More Technical Analysis:

Today's close gave us the highest Volume day, and the highest closing price since June 29th when they announced Orphan Status for their lead drug...Today's candle looks very Bullish, even if it is AT the upper BB...The 5MA has crossed up thru the 15MA very sharply, which hasn't happened for a long time...The CCI is getting a bit toppy by rising above the +100 line, but Stochastics isn't very Overbought yet with a reading of only 69 for the fast line, which is above the slow line and upticking very sharply...The MACD is looking Bullish with the Histogram upticking sharply today (blue bars), and the fast line did too and is above the slow line which is also upticking...



The chart below has a few more technical indicators on it: Starting with the dark green Chaikin Money Flow at the top, it's at a two month high...On Balance Volume (red line) and Accumulation/Distribution (black line) are upticking sharply, and also close to two month highs...We already covered the CCI, STO, and the MACD on the previous chart...The ADX shows the green DI+ is above the red DI- and they are diverging further apart...The green line at the bottom is the RSI - Relative Strength Index, and it's AT two month highs...

Add everything together, and these charts are screaming BULLishness!...

The only negative I can see is today's candle AT the upper BB, because it is almost always a level of Resistance...Only increasing Volume early next week will be able to start to bend the upper BB up, and allow the price to keep bumping up against it as it moves up...



The weekly chart clearly shows that CYCC is in the bottoming process...It's bouncing up off of the lower BB, this week's candlestick is a Bullish Hammer (and so was last week's, and the week before was an Inverted Hammer showing a Reversal)...It convincingly closed above the 5MA for the first time since early June...The weekly Volume doesn't look so great because each day this week preceding today had record setting low Volume, so the weekly averages out to roughly the same as the weeks before this one...The CCI has just given a Buy Signal by crossing up thru the -100 line...Stochastics is fighting it's way up out of totally Oversold territory, and the fast line has finally convincingly crossed up above the slow line, which is Bullish...The MACD Histogram (blue bars) had a nice uptick this week, and the MACD's fast line (black) looks to be finally leveling off...IF this stock continues to go up next week, the Resistance Levels ahead of it are the 15MA at $1.91 and the middle BB at $2.04 and if it can start closing above the middle BB there was some Resistance for four weeks at $2.20 from mid-May to early June...There is some more Resistance in the $2.50 -2.55 area in the beginning of May, and then it has NO more Resistance after that all the way up to the upper BB Resistance at $2.71 But if it is headed up to the upper BB on the weekly chart, by the time it takes it to get up there, the upper BB will have dropped some from what it reads now...

This weekly chart is beginning to show MUCH more Bull than Bear!...



I think we are overdue some GREAT news, and it could come as early as the pre-market session on Monday, which is a favorite time this company releases PR's...If not, we are SURE to hear something interesting later in the week, when they announce Q2 earnings numbers and hold a conference call to discuss important things going on with the company and the FDA and hopefully some real clarification about what's going on with the SPA...

Good Luck to All CYCC Investors!...

zigzagman

CYCC - Cyclacel Pharmaceuticals - Announces FDA Orphan Drug Designation for Sapacitabine in Both AML and MDS:

Press Release Source: Cyclacel Pharmaceuticals, Inc. On Thursday July 1, 2010, 7:00 am EDT

BERKELEY HEIGHTS, N.J., July 1, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's sapacitabine (CYC682) product candidate for the treatment of both acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

"Orphan drug designation for both AML and MDS significantly strengthens the value proposition represented by sapacitabine and enhances our opportunity to advance this promising product candidate to late stage clinical development and commercialization," said Spiro Rombotis, President and Chief Executive Officer of Cyclacel.

Sapacitabine, a cell cycle modulating nucleoside analogue, is in Phase 2 studies for the treatment of AML in the elderly, MDS and lung cancer. Cyclacel has reported Phase 2 results from ongoing studies in AML and MDS. The company plans to advance sapacitabine into pivotal Phase 3 development in 2010. During the first quarter of 2010, the company submitted a Special Protocol Assessment (SPA) request to the FDA for a randomized Phase 3 study of sapacitabine in elderly patients with AML.

Orphan drug designation entitles Cyclacel Pharmaceuticals to seven years of marketing exclusivity for sapacitabine upon regulatory approval, as well as the opportunity to apply for grant funding from the U.S. government to defray costs of clinical trial expenses, tax credits for clinical research expenses and a potential waiver of the FDA's application user fee. Orphan status is granted by the FDA to promote the development of new drug therapies for the treatment of diseases that affect fewer than 200,000 individuals in the United States.

http://finance.yahoo.com/news/Cyclacel-Pharmaceuticals-pz-2152455345.html?x=0&.v=1

CYCC - Cyclacel Pharmaceuticals Drug 'Sapacitabine' was Granted Orphan Drug Status by the FDA for the Treatment of Myelodysplastic Syndrome:

Orphan Status is verified on the FDA website:

Here is some information about what Orphan Status means...

CONGRESSIONAL FINDINGS FOR THE ORPHAN DRUG ACT

The Congress finds that...

(1) there are many diseases and conditions, such as Huntington's disease, myoclonus, ALS (Lou Gehrig's disease), Tourette syndrome, and muscular dystrophy which affect such small numbers of individuals residing in the United States that the diseases and conditions are considered rare in the United States;

(2) adequate drugs for many of such diseases and conditions have not been developed;

(3) drugs for these diseases and conditions are commonly referred to as "orphan drugs";

(4) because so few individuals are affected by any one rare disease or condition, a pharmaceutical company which develops an orphan drug may reasonably expect the drug to generate relatively small sales in comparison to the cost of developing the drug and consequently to incur a financial loss;

(5) there is reason to believe that some promising orphan drugs will not be developed unless changes are made in the applicable Federal laws to reduce the costs of developing such drugs and to provide financial incentives to develop such drugs; and

(6) it is in the public interest to provide such changes and incentives for the development of orphan drugs.

Here is a link to the FDA site that explains a lot more about this subject:

http://www.fda.gov/forindustry/developingproductsforrarediseasesconditions/overview/ucm119477.htm

As you can see, Sapacitabine was granted Orphan Status for the treatment of myelodysplastic syndrome on June 24, 2010 and this is VERY GOOD news for CYCC...IMO

The image below is found here, and there is a daily chart that's showing a lot of improvement at the bottom of this post...Just take a look at the Volume that poured in when this news was discovered...I find it a bit unusual that the company has yet to put out a Press Release about this very positive development...I have sent an email to the Investors Relations representative at the company, and will post his reply when I get it...

http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=263408

CYCC - Cyclacel Pharmaceuticals to Report New Sapacitabine Phase 2 Interim Results in MDS at the American Society of Clinical Oncology Annual Meeting:

http://finance.yahoo.com/news/Cyclacel-Pharmaceuticals-to-pz-4081723539.html?x=0&.v=1

BERKELEY HEIGHTS, N.J., May 21, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC - News) (Nasdaq:CYCCP - News) announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.

The Phase 2 study is evaluating sapacitabine administered as a single agent in older patients with myelodysplastic syndromes, or MDS, after treatment with hypomethylating agents.

Oral poster discussion details are as follows:

"A randomized phase 2 study of sapacitabine in MDS refractory to hypomethylating agents"
Date/Time: Monday, June 7, 2010, 2:00 P.M. - 6:00 P.M. Eastern Time
Abstract Number: 6528
Location: E450a

Discussion time: 5:00 P.M. - 6:00 P.M. Eastern Time
Location: E354a

Sapacitabine Phase 2 study in MDS:

The MDS study is designed as a protocol amendment expanding the fully enrolled Phase 2 trial of sapacitabine in acute myeloid leukemia, or AML, to include a stratum of patients with MDS refractory to hypomethylating agents. Patients with MDS often progress to AML. The primary objective of the MDS stratum is to evaluate the 1-year survival rate of three dosing schedules of sapacitabine. Secondary objectives are to assess the number of patients who have achieved CR or CRp, PR, hematological improvement and their corresponding durations, transfusion requirements, number of hospitalization days and safety. The MDS study uses a selection design with the objective of identifying a dosing schedule which produces a better 1-year survival rate in the event that all three dosing schedules are active.

The abstract is available online at:

http://abstract.asco.org/AbstView_74_54011.html

VIDEO - POZN Gets FDA Approval For Pain Drug Vimovo:

Friday was a great day for Pozen Inc.

The FDA gave full approval to their drug Vimovo. It can now be sold all across America...

$POZN Gets FDA Approval for Pozen Inc.'s Pain Drug - Vimovo !...

POZN - US FDA OK's AstraZeneca, Pozen Inc.'s Pain Drug:

Fri Apr 30, 2010 5:19pm EDT

* Agency clears drug for U.S. market

* Vimovo includes naproxen and Nexium ingredient

* Pozen shares up more than 21 percent after-hours

WASHINGTON, April 30 (Reuters) - The U.S. Food and Drug Administration has approved AstraZeneca Plc (AZN.L) and Pozen Inc's (POZN.O) pain drug Vimovo, an agency spokeswoman told Reuters on Friday.

Vimovo is a fixed-dose combination of the anti-inflammatory drug naproxen and an immediate release version of esomeprazole, the active ingredient in AstraZeneca's acid reflux treatment Nexium.

Shares of Pozen were up more than 21 percent, or about $2.30, in after-hours trading on Friday, trading at $13.15, after earlier closing at $10.85. (Reporting by Susan Heavey; additional reporting by Ben Hirschler in London and Vidya Loganathan in Bangalore; editing by Carol Bishopric)

http://www.reuters.com/article/idCNN3015546220100430?rpc=44

POZN is currently halted...Per the Nasdaq.com website:

http://www.nasdaqtrader.com/Trader.aspx?id=TradeHalts

No time is given for resumption of trading...

There was a huge Bear Raid at 12:37 this afternoon, as the MM's took out all of the stop-loss limit orders people had in place:



POZN After-Hours Chart shows it closed at $13.15 when it was halted for "news pending":

$DNDN - Dendreon Gets FDA Approval For Provenge To Treat Prostate Cancer!:

FDA Approves a Cellular Immunotherapy for Men with Advanced Prostate Cancer:

The U.S. Food and Drug Administration today approved Provenge (sipuleucel-T), a new therapy for certain men with advanced prostate cancer that uses their own immune system to fight the disease.

Provenge is indicated for the treatment of asymptomatic or minimally symptomatic prostate cancer that has spread to other parts of the body and is resistant to standard hormone treatment.

Prostate cancer is the second most common type of cancer among men in the United States, behind skin cancer, and usually occurs in older men. In 2009, an estimated 192,000 new cases of prostate cancer were diagnosed and about 27,000 men died from the disease, according to the National Cancer Institute.

“The availability of Provenge provides a new treatment option for men with advanced prostate cancer, who currently have limited effective therapies available,” said Karen Midthun, M.D., acting director of the FDA’s Center for Biologics Evaluation and Research.

Provenge is an autologous cellular immunotherapy, designed to stimulate a patient’s own immune system to respond against the cancer. Each dose of Provenge is manufactured by obtaining a patient’s immune cells from the blood, using a machine in a process known as leukapheresis. To enhance their response against the cancer, the immune cells are then exposed to a protein that is found in most prostate cancers, linked to an immune stimulating substance. After this process, the patient’s own cells are returned to the patient to treat the prostate cancer. Provenge is administered intravenously in a three-dose schedule given at about two-week intervals.

The effectiveness of Provenge was studied in 512 patients with metastatic hormone treatment refractory prostate cancer in a randomized, double-blind, placebo-controlled, multicenter trial, which showed an increase in overall survival of 4.1 months. The median survival for patients receiving Provenge treatments was 25.8 months, as compared to 21.7 months for those who did not receive the treatment.

Almost all of the patients who received Provenge had some type of adverse reaction. Common adverse reactions reported included chills, fatigue, fever, back pain, nausea, joint ache and headache. The majority of adverse reactions were mild or moderate in severity. Serious adverse reactions, reported in approximately one quarter of the patients receiving Provenge, included some acute infusion reactions and stroke. Cerebrovascular events, including hemorrhagic and ischemic strokes, were observed in 3.5 percent of patients in the Provenge group compared with 2.6 percent of patients in the control group.

Provenge is manufactured by Seattle-based Dendreon Corp.

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm210174.htm

DNDN was halted at 12:34 pm ET, and remains halted at 2:10 pm...Just before the halt, it jumped up almost 15% and up over $7.00 in three minutes from $40. to $47.